Financial News

Nicox: Opening of U.S. Development Office in Research Triangle Park, North Carolina

  • Company to relocate its growing U.S. development operations to the North Carolina biotech hub in Research Triangle Park
  • Nicox Research Triangle Park team strengthens and expands Nicox’s development capabilities, with a focus on advancing NCX 470 and NCX 4251

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), an international ophthalmology company,

Read more

Nicox Ordinary and Extraordinary General Meetings convened on May 3, 2018

Dear Shareholder,
I am writing to you to request your continued support for Nicox by voting in the upcoming Nicox Ordinary and Extraordinary General Meetings to be convened on May 3, 2018.
2017 was a pivotal year for Nicox, marked by the approval of two of our assets by the U.S. Food and Drug Administration. VYZULTATM,

Read more

Nicox to Present at Upcoming Conferences

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), international ophthalmology company, today announced that members of Nicox’ management team will participate in the following conferences in April 2018:

  • Gavin Spencer, Executive Vice President, Chief Business Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 9:00 a.m.
Read more
More news